InvestSMART

CurveBeam AI Limited (ASX:CVB)

ALERT: Price-sensitive ASX Announcement for CVB
Current share price for CVB : $0.018 -0.064 (-78.05%)+
Announcement
Release
30 Oct 2025 9:36AM
Price at Release
$0.082
Full Release
download
Summary
CurveBeam AI Limited reported significant activities for Q1 FY26, including increased purchase orders and the successful completion of a fundraising placement. The company is advancing its strategy in China through a partnership with Weiying Intelligent Medical Technology, which involves the local manufacturing and distribution of its products. This move is expected to provide a short-term boost to sales and facilitate market entry into China. Additionally, the company has secured a vendor financing facility and is maintaining its timeline for FDA clearance for a new software module. The strategic initiatives are aimed at reducing costs, expanding market access, and enhancing global competitiveness.
Key Points
  • Purchase orders for four devices in Q1 FY26, a growth of 33.3% over the prior period.
  • Completion of a placement to raise A$6.5 million.
  • Increased engagement with a vendor for the validation of the enhanced HiRise™ system.
  • Signed final contracts with Weiying Intelligent Medical Technology for Chinese distribution and manufacturing.
  • Vendor financing facility agreement established for approximately A$18 million.
  • Target for FDA clearance of BMD MDCT software module by mid-CY26.
  • Capital injection at reduced dilution through a A$10 million investment.
  • China will initially receive US manufactured HiRise, boosting company sales.
  • China manufacturing strategy aims to reduce costs and increase margins.
  • A dual-factory strategy to mitigate supply chain and tariff-related risks.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.